Search

Your search keyword '"Katarina Gyuraszova"' showing total 7 results
Start Over Author "Katarina Gyuraszova" Publication Year Range Last 3 years
7 results on '"Katarina Gyuraszova"'

1. Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma

Author

Pooyeh Farahmand, Katarina Gyuraszova, Claire Rooney, Ximena L. Raffo-Iraolagoitia, Geeshath Jayasekera, Ann Hedley, Emma Johnson, Tatyana Chernova, Gaurav Malviya, Holly Hall, Tiziana Monteverde, Kevin Blyth, Rodger Duffin, Leo M. Carlin, David Lewis, John Le Quesne, Marion MacFarlane, and Daniel J. Murphy

Subjects
mesothelioma, asbestos, cancer therapy, GM mouse model, macrophages, Toxicology. Poisons, RA1190-1270
Abstract

Hypothesis: Asbestos-driven inflammation contributes to malignant pleural mesothelioma beyond the acquisition of rate-limiting mutations.Methods: Genetically modified conditional allelic mice that were previously shown to develop mesothelioma in the absence of exposure to asbestos were induced with lentiviral vector expressing Cre recombinase with and without intrapleural injection of amosite asbestos and monitored until symptoms required euthanasia. Resulting tumours were examined histologically and by immunohistochemistry for expression of lineage markers and immune cell infiltration.Results: Injection of asbestos dramatically accelerated disease onset and end-stage tumour burden. Tumours developed in the presence of asbestos showed increased macrophage infiltration. Pharmacological suppression of macrophages in mice with established tumours failed to extend survival or to enhance response to chemotherapy.Conclusion: Asbestos-driven inflammation contributes to the severity of mesothelioma beyond the acquisition of rate-limiting mutations, however, targeted suppression of macrophages in established epithelioid mesothelioma showed no therapeutic benefit.

Published
2023
Full Text
View/download PDF

2. Table S4 from Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma

Author

Daniel J. Murphy, Jennifer P. Morton, Owen J. Sansom, Seth B. Coffelt, Leo M. Carlin, Andrew V. Biankin, William Clark, Colin Nixon, Katarina Gyuraszova, Saadia A. Karim, Curtis Rink, Sarah Neidler, Robin Shaw, Rosanna Upstill-Goddard, Björn Kruspig, Sarah Laing, Ann Hedley, Declan Whyte, Robert Wiesheu, Ximena Raffo-Iraolagoitia, Tiziana Monteverde, and Nathiya Muthalagu

Abstract

Spreadsheet of genes co-regulated by MYC & Miz1 in KMC PDAC cells

Published
2023

3. Figures S1-S6 & Tables S1 & S2 from Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress

Author

Daniel J. Murphy, Sara R. Zanivan, Owen J. Sansom, Graeme I. Murray, Hiroyasu Esumi, Martin Drysdale, Colin Nixon, Allan McVie, David Sumpton, Amy Bryson, Silvija Svambaryte, Mokdad Mezna, Jacqueline Tait-Mulder, Katarina Gyuraszova, Martina Brucoli, Lisa Neilson, Sergio Lilla, Gabriela Kalna, Ann Hedley, Björn Kruspig, Tiziana Monteverde, Fatih Ceteci, Meera Raja, Nathiya Muthalagu, and Jennifer Port

Abstract

Merged supplementary Figures & Figure legends and Tables & Table legends

Published
2023

4. Supplementary Table 3 from Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress

Author

Daniel J. Murphy, Sara R. Zanivan, Owen J. Sansom, Graeme I. Murray, Hiroyasu Esumi, Martin Drysdale, Colin Nixon, Allan McVie, David Sumpton, Amy Bryson, Silvija Svambaryte, Mokdad Mezna, Jacqueline Tait-Mulder, Katarina Gyuraszova, Martina Brucoli, Lisa Neilson, Sergio Lilla, Gabriela Kalna, Ann Hedley, Björn Kruspig, Tiziana Monteverde, Fatih Ceteci, Meera Raja, Nathiya Muthalagu, and Jennifer Port

Abstract

Excel spreadsheet of NUAK1 inhibitor induced phospho-peptide alterations

Published
2023

5. Supplementary Methods from Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress

Author

Daniel J. Murphy, Sara R. Zanivan, Owen J. Sansom, Graeme I. Murray, Hiroyasu Esumi, Martin Drysdale, Colin Nixon, Allan McVie, David Sumpton, Amy Bryson, Silvija Svambaryte, Mokdad Mezna, Jacqueline Tait-Mulder, Katarina Gyuraszova, Martina Brucoli, Lisa Neilson, Sergio Lilla, Gabriela Kalna, Ann Hedley, Björn Kruspig, Tiziana Monteverde, Fatih Ceteci, Meera Raja, Nathiya Muthalagu, and Jennifer Port

Abstract

Supplementary Methods

Published
2023

6. Data from Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma

Author

Daniel J. Murphy, Jennifer P. Morton, Owen J. Sansom, Seth B. Coffelt, Leo M. Carlin, Andrew V. Biankin, William Clark, Colin Nixon, Katarina Gyuraszova, Saadia A. Karim, Curtis Rink, Sarah Neidler, Robin Shaw, Rosanna Upstill-Goddard, Björn Kruspig, Sarah Laing, Ann Hedley, Declan Whyte, Robert Wiesheu, Ximena Raffo-Iraolagoitia, Tiziana Monteverde, and Nathiya Muthalagu

Abstract

MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the pancreatic phenotypes arising in mice from an approximation of MYC trisomy. We show that this level of MYC alone suffices to drive pancreatic neuroendocrine tumors, and to accelerate progression of KRAS-initiated precursor lesions to metastatic pancreatic ductal adenocarcinoma (PDAC). Our phenotype exposed suppression of the type I interferon (IFN) pathway by the combined actions of MYC and KRAS, and we present evidence of repressive MYC–MIZ1 complexes binding directly to the promoters of the genes encodiing the type I IFN regulators IRF5, IRF7, STAT1, and STAT2. Derepression of IFN regulator genes allows pancreatic tumor infiltration by B and natural killer (NK) cells, resulting in increased survival.Significance:We define herein a novel mechanism of evasion of NK cell–mediated immunity through the combined actions of endogenously expressed mutant KRAS and modestly deregulated expression of MYC, via suppression of the type I IFN pathway. Restoration of IFN signaling may improve outcomes for patients with PDAC.This article is highlighted in the In This Issue feature, p. 747

Published
2023

7. Supplementary Material from Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma

Author

Daniel J. Murphy, Jennifer P. Morton, Owen J. Sansom, Seth B. Coffelt, Leo M. Carlin, Andrew V. Biankin, William Clark, Colin Nixon, Katarina Gyuraszova, Saadia A. Karim, Curtis Rink, Sarah Neidler, Robin Shaw, Rosanna Upstill-Goddard, Björn Kruspig, Sarah Laing, Ann Hedley, Declan Whyte, Robert Wiesheu, Ximena Raffo-Iraolagoitia, Tiziana Monteverde, and Nathiya Muthalagu

Abstract

6 supplementary Figures with legends under each; 3 Supplementary Tables; Supplementary Methods and References

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results